Contract Pharma2d
Boehringer Ingelheim Taps Salipro Biotech to Accelerate Pipeline Programs
Salipro Biotech has signed a research and license agreement with Boehringer Ingelheim to accelerate the development of ...
Fierce Biotech3d
Boehringer Ingelheim teams with Veeva to launch new R&D platform One Medicine
Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...
Contract Pharma4d
Cognizant and Boehringer Ingelheim Launch One Medicine Platform
The One Medicine Platform replaces 20+ legacy platforms—unifying medicinal development processes & data sources into a ...
Reuters8mon
Boehringer Ingelheim International GmbH
Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused cancer, both of which had previously ended with hung juries. November 22 ...
The Hamilton Spectator23d
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
Ingelheim, Germany, 20 February 2025 – Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial ...
Veeva, Boehringer Ingelheim partner to launch ‘One Medicine Platform’
Boehringer Ingelheim and Veeva Systems have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They ...